273 related articles for article (PubMed ID: 14601057)
1. DNA methylation of RASSF1A, HIN-1, RAR-beta, Cyclin D2 and Twist in in situ and invasive lobular breast carcinoma.
Fackler MJ; McVeigh M; Evron E; Garrett E; Mehrotra J; Polyak K; Sukumar S; Argani P
Int J Cancer; 2003 Dec; 107(6):970-5. PubMed ID: 14601057
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of promoter hypermethylation detection in serum as a diagnostic tool for breast carcinoma in Korean women.
Kim JH; Shin MH; Kweon SS; Park MH; Yoon JH; Lee JS; Choi C; Fackler MJ; Sukumar S
Gynecol Oncol; 2010 Aug; 118(2):176-81. PubMed ID: 20466412
[TBL] [Abstract][Full Text] [Related]
3. Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lung.
Mehrotra J; Vali M; McVeigh M; Kominsky SL; Fackler MJ; Lahti-Domenici J; Polyak K; Sacchi N; Garrett-Mayer E; Argani P; Sukumar S
Clin Cancer Res; 2004 May; 10(9):3104-9. PubMed ID: 15131050
[TBL] [Abstract][Full Text] [Related]
4. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
5. HIN-1, a putative cytokine highly expressed in normal but not cancerous mammary epithelial cells.
Krop IE; Sgroi D; Porter DA; Lunetta KL; LeVangie R; Seth P; Kaelin CM; Rhei E; Bosenberg M; Schnitt S; Marks JR; Pagon Z; Belina D; Razumovic J; Polyak K
Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9796-801. PubMed ID: 11481438
[TBL] [Abstract][Full Text] [Related]
6. Detection of RASSF1A aberrant promoter hypermethylation in sputum from chronic smokers and ductal carcinoma in situ from breast cancer patients.
Honorio S; Agathanggelou A; Schuermann M; Pankow W; Viacava P; Maher ER; Latif F
Oncogene; 2003 Jan; 22(1):147-50. PubMed ID: 12527916
[TBL] [Abstract][Full Text] [Related]
7. Cadherin-catenin complex dissociation in lobular neoplasia of the breast.
Morrogh M; Andrade VP; Giri D; Sakr RA; Paik W; Qin LX; Arroyo CD; Brogi E; Morrow M; King TA
Breast Cancer Res Treat; 2012 Apr; 132(2):641-52. PubMed ID: 22080244
[TBL] [Abstract][Full Text] [Related]
8. Allele loss and promoter hypermethylation of VHL, RAR-beta, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma.
Kuroki T; Trapasso F; Yendamuri S; Matsuyama A; Alder H; Mori M; Croce CM
Cancer Res; 2003 Jul; 63(13):3724-8. PubMed ID: 12839965
[TBL] [Abstract][Full Text] [Related]
9. Methylation biomarkers for pleomorphic lobular breast cancer - a short report.
Moelans CB; Vlug EJ; Ercan C; Bult P; Buerger H; Cserni G; van Diest PJ; Derksen PW
Cell Oncol (Dordr); 2015 Oct; 38(5):397-405. PubMed ID: 26392358
[TBL] [Abstract][Full Text] [Related]
10. Epigenetic progression of columnar cell lesions of the breast to invasive breast cancer.
Verschuur-Maes AH; de Bruin PC; van Diest PJ
Breast Cancer Res Treat; 2012 Dec; 136(3):705-15. PubMed ID: 23104224
[TBL] [Abstract][Full Text] [Related]
11. Epigenetic alterations by methylation of RASSF1A and DAPK1 promoter sequences in mammary carcinoma detected in extracellular tumor DNA.
Ahmed IA; Pusch CM; Hamed T; Rashad H; Idris A; El-Fadle AA; Blin N
Cancer Genet Cytogenet; 2010 Jun; 199(2):96-100. PubMed ID: 20471512
[TBL] [Abstract][Full Text] [Related]
12. Correlation between CpG methylation profiles and hormone receptor status in breast cancers.
Feng W; Shen L; Wen S; Rosen DG; Jelinek J; Hu X; Huan S; Huang M; Liu J; Sahin AA; Hunt KK; Bast RC; Shen Y; Issa JP; Yu Y
Breast Cancer Res; 2007; 9(4):R57. PubMed ID: 17764565
[TBL] [Abstract][Full Text] [Related]
13. Tumor suppressor genes are frequently methylated in lymph node metastases of breast cancers.
Feng W; Orlandi R; Zhao N; Carcangiu ML; Tagliabue E; Xu J; Bast RC; Yu Y
BMC Cancer; 2010 Jul; 10():378. PubMed ID: 20642860
[TBL] [Abstract][Full Text] [Related]
14. Detection of RASSF1A and RARbeta hypermethylation in serum DNA from breast cancer patients.
Shukla S; Mirza S; Sharma G; Parshad R; Gupta SD; Ralhan R
Epigenetics; 2006; 1(2):88-93. PubMed ID: 17998817
[TBL] [Abstract][Full Text] [Related]
15. CCND1- and ERBB2-gene deregulation and PTEN mutation analyses in invasive lobular carcinoma of the breast.
Mercapide J; Zhang SY; Fan X; Furió-Bacete V; Schneider J; López de la Osa I; Patchefsky AS; Klein-Szanto AJ; Castresana JS
Mol Carcinog; 2002 Sep; 35(1):6-12. PubMed ID: 12203362
[TBL] [Abstract][Full Text] [Related]
16. Quantitative promoter hypermethylation profiles of ductal carcinoma in situ in North American and Korean women: Potential applications for diagnosis.
Lee JS; Fackler MJ; Teo WW; Lee JH; Choi C; Park MH; Yoon JH; Zhang Z; Argani P; Sukumar S
Cancer Biol Ther; 2008 Sep; 7(9):1398-406. PubMed ID: 18769130
[TBL] [Abstract][Full Text] [Related]
17. Frequent promoter hypermethylation of BRCA2, CDH13, MSH6, PAX5, PAX6 and WT1 in ductal carcinoma in situ and invasive breast cancer.
Moelans CB; Verschuur-Maes AH; van Diest PJ
J Pathol; 2011 Oct; 225(2):222-31. PubMed ID: 21710692
[TBL] [Abstract][Full Text] [Related]
18. Applicability of HIN-1, MGMT and RASSF1A promoter methylation as biomarkers for detecting field cancerization in breast cancer.
Spitzwieser M; Holzweber E; Pfeiler G; Hacker S; Cichna-Markl M
Breast Cancer Res; 2015 Sep; 17(1):125. PubMed ID: 26370119
[TBL] [Abstract][Full Text] [Related]
19. Promoter hypermethylation of the death-associated protein kinase gene in breast cancer is associated with the invasive lobular subtype.
Lehmann U; Celikkaya G; Hasemeier B; Länger F; Kreipe H
Cancer Res; 2002 Nov; 62(22):6634-8. PubMed ID: 12438260
[TBL] [Abstract][Full Text] [Related]
20. Loss of heterozygosity on chromosome 11q13 in lobular lesions of the breast using tissue microdissection and polymerase chain reaction.
Nayar R; Zhuang Z; Merino MJ; Silverberg SG
Hum Pathol; 1997 Mar; 28(3):277-82. PubMed ID: 9042790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
